Brightiva was not developed in a laboratory by a committee. It was developed by a psychiatrist who spent years watching patients struggle with conditions that conventional treatment could not resolve, and who built a better answer. Brightiva represents a clinical breakthrough made accessible through exceptional execution.
Dr. Paul Hebig is a board-certified psychiatrist with over 22 years of clinical experience and a long-standing commitment to finding better answers for patients that conventional treatment has struggled to help. Over the course of more than six years treating thousands of patients with oral ketamine therapy, Dr. Hebig observed firsthand what this class of treatment could offer — and where it could go further.
That clinical experience became the foundation for Brightiva. Recognizing that ketamine’s therapeutic potential could be meaningfully extended and modulated through a precisely engineered combination of compounds, Dr. Hebig developed a proprietary three-component formulation and a structured treatment protocol. The result is a therapy that, based on his experience, may deliver more complete and sustained relief for patients living with treatment-resistant depression, anxiety, PTSD, and substance use disorders.
Brightiva is the expression of Dr. Hebig’s conviction that patients who have exhausted conventional options deserve something better. He has dedicated his career to making that a reality.
Kenneth Cooper is a highly accomplished executive with over 25 years of experience across financial services and healthcare. As a founding member and CEO of North American Dental Group, he led the company from inception to one of the largest privately held dental service organizations in the United States, with more than 300 locations across 16 states. Recognized by Forbes as a Top 20 CEO, his leadership spanned the full breadth of the organization, from capital markets and corporate development to operations and post-merger integration.
Mr. Cooper serves as founder and CEO of PUR Health Holdings, a behavioral health platform dedicated to expanding access to psychiatric care across clinical and telehealth settings. He is an active board member of several organizations serving behavioral health and addiction services.
Dr. Hebig and Mr. Cooper are both strong advocates for the use of safe and effective treatment at the cutting edge of psychiatric medicine, pioneering a way to make one of the latest breakthroughs in ketamine treatment available and affordable.
Dr. Hebig developed The Brightiva formulation and Mr. Cooper brought the experience, infrastructure, and commitment needed to make it available to the patients who need it most.
Hear from doctors & patients from across the Brightiva Network.
I have a long-term patient with chronic refractory depression who was recently treated with Brightiva. This patient had a quite significant improvement in her depressive symptoms after treatment with this new agent. She has been treated with many medications in the past, including ketamine, but her demeanor and attitude improved with Brightiva.
Founder, Whole Family Health Center — Vero Beach, Florida
This made a noticeable improvement in my depression. It helped me feel better.
Patient Testimonial
I feel totally amazing and more focused!
Patient Testimonial
… my experience with this treatment is like night and day. My depression is slowly getting better, and I am now able to interact with my family.
Patient Testimonial
… working with Dr. Hebig has been one of the most life-changing experiences I have had …
Patient Testimonial
The Brightiva Network is the credentialed community of licensed prescribers who deliver Brightiva to patients nationwide. From the day a physician is approved, they have access to everything needed to begin treating patients with confidence.
Two people built Brightiva for one reason: because patients who have run out of options deserve something better. If that is you or someone you care for, the next step starts here.